Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for catatract returned no results
Showing 31 to 45 of 57 results for cataract

  1. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA460

  2. Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

    Evidence-based recommendations on Holoclar (a layer of cells grown from cells taken from your own eye) for treating limbal stem cell deficiency in adults with eye burns.

    Technology appraisal guidance
    Published
    16 August 2017
    View recommendations

    Sections for TA467

  3. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)

    Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Last updated
    20 May 2024
    View recommendations

    Sections for TA155

  4. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA294

  5. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    22 July 2015
    View recommendations

    Sections for TA346

  6. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.

    Technology appraisal guidance
    Last updated
    20 May 2024
    View recommendations

    Sections for TA283

  7. Eltrombopag for treating chronic immune thrombocytopenia (TA293)

    Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Last updated
    26 October 2018
    View recommendations

    Sections for TA293

  8. AI technologies for detecting diabetic retinopathy (MIB265)

    NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .

    Medtech innovation briefing
    Published
    6 July 2021

  9. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

    NICE guideline
    Published
    9 February 2016
    View recommendations

    Sections for NG34

  10. Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma (IPG612)

    Evidence-based recommendations on microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma in adults. This involves putting a tiny gelatin tube (stent) under the skin at the base of the eye to create a new drainage channel for excess fluid.

    Interventional procedures guidance
    Published
    25 April 2018
    View recommendations

    Sections for IPG612

  11. Interventions to manage cystoid macular oedema:- What is the most effective postoperative medical management for cystoid macular oedema?

    oedema. Source guidance details Comes from guidance Cataracts in adults: management Number NG77 Date issued October

    Research recommendation
    Published
    18 October 2018

  12. Toric lenses for astigmatism:- What is the cost effectiveness of toric lenses compared with on-axis or limbal-relaxing incision surgery, or non-toric lenses with no further intervention, in an NHS context, taking account of the whole care pathway cost implications from pre- to postoperative phases, stratified by the preoperative level of astigmatism?

    their use. Source guidance details Comes from guidance Cataracts in adults: management Number NG77 Date issued October

    Research recommendation
    Published
    6 November 2018

  13. Brain tumours (primary) and brain metastases in over 16s (QS203)

    This quality standard covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in adults (aged 16 or over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 December 2021
    View quality statements

    Sections for QS203

  14. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

    Technology appraisal guidance
    Published
    27 October 2010
    View recommendations

    Sections for TA204

  15. Omalizumab for treating severe persistent allergic asthma (TA278)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.

    Technology appraisal guidance
    Published
    24 April 2013
    View recommendations

    Sections for TA278